
Stan Bergstein's Daily Racing Form columnsWith permission of Daily Racing Form,
Stan Bergstein’s bi-weekly
columns for that publication will appear
here every other week.
February 28, 2002
Blood-boosters present a real
threat
If you watched the Olympic winter games, or read
about them, you know that Johann Muehlegg, the German who skies for
Spain, won three gold medals in grueling stamina events, and then lost
one of them - the 50-kilometer classic - because of a positive test for
darbepoetin.
What's darbepoetin?
It's the next step past erythropoietin, or EPO, as
a blood enhancer, a stimulant of red blood cells which carry oxygen to
muscles, and thus reduce fatigue and add stamina.
It was not developed to aid athletes, including
equine athletes, but it is being used for that.
Its legal medical purpose is to help victims of
severe anemia induced by cancer and kidney disease, but along the way
professional cyclists and skiers discovered it and decided to boost
their healthy natural stamina.
But it already is old hat.
Enter the new super-booster, a drug called Aranesp,
developed by pharmaceutical giant Amgen, which also developed EPO. And
in Russia, another product called Perftoran, which allows the blood to
carry 20 percent more oxygen than normal, but reportedly with some
serious side effects. You can buy it in Moscow without a prescription.
Aranesp is considered a medical breakthrough of
tremendous importance, and also a huge economic booster for Amgen in its
competition with Johnson & Johnson. Amgen's chairman says the future of
the company will be tied to Aranesp over the next several years. EPO is
sold by Johnson & Johnson under the brand name Procrit in the United
States, and The Wall Street Journal says it is that company's biggest
seller, dwarfing its baby shampoo and Band-Aid sales. It accounts for 19
percent of the company's profit, the largest share, and is expected to
bring in $3 billion (that's with a B) this year. Amgen says it sold
$1.96 billion dollars worth of Epogen, its brand of EPO, last year.
Athletes like world-class skiers and cyclists who
use EPO, or now Aranesp, or darbepoetin, do not have anemia or cancer or
kidney disease. They have a hunger and craving for success at any cost.
And so do trainers who use the stuff on horses.
There is a spirit of denial about this, and while I
highly respect and believe top-of-the-sport trainers like Richard
Mandella and Thomas Amoss when they say they aren't aware of any
trainers who use these things, I also believe lesser trainers who tell
me the substances are being used regularly by the thin slice of cheaters
looking for an edge.
I also believe cyclist trainer Antoine Veyer when
he says, "Of course Nesp" - the bikers' word for Aranesp - "is being
used. Everybody knows it. It is a new drug. You can buy it now but in
doping control you cannot detect it." And unfortunately I believe, with
fear and trepidation, researcher Dr. Bengt Saltin, who says the active
molecule in Aranesp is "10 times more powerful" than that in EPO, which
the British Broadcasting Company calls "the current drug of choice for
cheaters in sport," and Dr. Michael Turner, a former medical officer for
the British Olympic Association, now working for the Lawn Tennis
Association and British Jockey Club, who says it is "inevitable" that
Aranesp will be used by those determined to cheat.
What does Amgen say about all this?
A spokesman says, "We can't stop people misusing
what is an important clinical medicine. The reason this company was put
together was to improve human life - not to enhance performance."
That leaves the problem, it seems, to the racing
chemists and drug testers and racing commissions and veterinarians and
trainers. The most surprising development in the Johann Muehlegg story
was that the Olympic committee says it has a test for EPO. If that is
true, then the Association of Racing Commissioners International and
various drug testing committees and veterinary groups should seek
Olympic drug researchers and find out how they tested Muehlegg so
conclusively that they stripped him of a gold medal, regardless of
whether that action stands or not on technical grounds.
Is it reasonable to believe that the small but
hugely damaging number of cheaters on bicycles and on skis and in
weight-lifting rooms are worlds apart from the small but hugely damaging
number of cheaters on the backstretch? Is it realistic to believe this
is not a problem so troublesome, whether widespread or not, that
detection and eradication by banishment should be the sport's number-one
priority, over marketing and advertising and TV commercials, all of
which it can negate?
Racing needs to make that choice, and make it
quickly. |